MicroSPECT/CT imaging of co-expressed HER2 and EGFR on subcutaneous human tumor xenografts in athymic mice using 111In-labeled bispecific radioimmunoconjugates

Breast Cancer Research and Treatment

Volumn 138, Issue 3, 2013, Pages 709-718

  Razumienko, Eva ^a   Dryden, Lindsay ^a   Scollard, Deborah ^a   Reilly, Raymond M ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Breast cancer; EGF; EGFR; HER2; Indium 111; Radioimmunoconjugates; SPECT

Indexed keywords

BISPECIFIC ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INDIUM 111; MACROGOL; PENTETIC ACID; TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING COMPETITION; BREAST CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMAGING SOFTWARE; IN VITRO STUDY; IN VIVO STUDY; MICROSPECTROPHOTOMETRY; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPECT SCANNER; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY SPECIFICITY; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN FAB FRAGMENTS; INDIUM RADIOISOTOPES; MALEIMIDES; MICE; MICE, NUDE; POLYETHYLENE GLYCOLS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84877795715     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2490-5     Document Type: Article

References (27)

1. Adams CW, Allison DE, Flagella K, Presta L, Clarke J, Dybdal N, McKeever K, Sliwkowski MX (2006) Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 55:717-727
2. Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109-119
3. 64Cu-DOTA-trastuzumab fab fragments for imaging subcutaneous HER2-positive tumor xenografts in athymic mice using microSPECT/CT or microPET/CT. EJNMMI Res 1:15
4. 111In-NLS-trastuzumab and are radiosensitized by methotrexate. J Nucl Med 49:1498-1505
5. DeFazio-Eli L, Strommen K, Dao-Pick T, Parry G, Goodman L, Winslow J (2011) Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action. Breast Cancer Res 13:R44
6. DiGiovanna MP, Lerman MA, Coffey RJ, Muller WJ, Cardiff RD, Stern DF (1998) Active signaling by Neu in transgenic mice. Oncogene 17:1877-1884
7. DiGiovanna MP, Stern DF, Edgerton SM, Whalen SG, Moore D 2nd, Thor AD (2005) Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol 23:1152-1160
8. du Manoir JM, Francia G, Man S, Mossoba M, Medin JA, Viloria-Petit A, Hicklin DJ, Emmenegger U, Kerbel RS (2006) Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin Cancer Res 12:904-916
9. Dua R, Zhang J, Nhonthachit P, Penuel E, Petropoulos C, Parry G (2010) EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance. Breast Cancer Res Treat 122:685-697
10. Ekerljung L, Wallberg H, Sohrabian A, Andersson K, Friedman M, Frejd FY, Stahl S, Gedda L (2012) Generation and evaluation of bispecific affibody molecules for simultaneous targeting of EGFR and HER2. Bioconjug Chem 23:1802-1811
11. Ekstrand AJ, Sugawa N, James CD, Collins VP (1992) Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci USA 89:4309-4313
12. 111In-Bn-DTPA-nimotuzumab with/without modification with nuclear translocation sequence (NLS) peptides: an Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-resistant breast cancer. Breast Cancer Res Treat 135:189-200
13. Gladhaug IP, Christoffersen T (1987) Kinetics of epidermal growth factor binding and processing in isolated intact rat hepatocytes. Dynamic externalization of receptors during ligand internalization. Eur J Biochem 164:267-275
14. 111In]DTPA-hEGF. Nucl Med Biol 34:887-896
15. Klapper LN, Kirschbaum MH, Sela M, Yarden Y (2000) Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 77:25-79
16. McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, Zhang B, Luus L, Overland R, Nguyen S, Gu J, Kohli N, Wallace M, Feldhaus MJ, Kudla AJ, Schoeberl B, Nielsen UB (2012) Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol Cancer Ther 11:582-593
17. Muller WJ, Arteaga CL, Muthuswamy SK, Siegel PM, Webster MA, Cardiff RD, Meise KS, Li F, Halter SA, Coffey RJ (1996) Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice. Mol Cell Biol 16:5726-5736
18. Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M, Yarden Y (1996) Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 15:2452-2467
19. Razumienko EJ, Scollard DA, Reilly RM (2012) Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates. J Nucl Med 53:1943-1950
20. 111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR. J Nucl Med 41:429-438
21. 111In for imaging human breast cancer. J Nucl Med 41:903-911
22. Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA, Arteaga CL (2007) Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 13:4909-4919
23. Robinson MK, Hodge KM, Horak E, Sundberg AL, Russeva M, Shaller CC, von Mehren M, Shchaveleva I, Simmons HH, Marks JD, Adams GP (2008) Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br J Cancer 99:1415-1425
24. Simpson RJ (2008) Estimation of free thiols and disulfide bonds using Ellman's reagent. CSH Protoc 9:1-8
25. 111In-trastuzumab (Herceptin) Fab fragments. Nucl Med Biol 32:51-58
26. Valverius EM, Bates SE, Stampfer MR, Clark R, McCormick F, Salomon DS, Lippman ME, Dickson RB (1989) Transforming growth factor alpha production and epidermal growth factor receptor expression in normal and oncogene transformed human mammary epithelial cells. Mol Endocrinol 3:203-214
27. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137